GENE ONLINE|News &
Opinion
Blog

2021-09-08| Licensing

Adaptimmune Therapeutics Breaks Rough Patch With New Multibillion-Dollar Collaboration

by Daniel Ojeda
Share To
The shares of the UK-based biopharmaceutical Adaptimmune Therapeutics have had a rough year, with its stock down more than 35% between the beginning of January and mid-August of this year. In comparison, the SP500 index was up more than 20% at the same time.

On September 7th, UK-based biopharmaceutical, Adaptimmune's stock jumped almost 29% following the news that it has signed a collaboration deal worth up to $3 billion with Genentech.

As part of the deal, Adaptimmune will receive $150 million in cash upfront, $150 million more over the next five years, and developmental, regulatory, and commercial milestones potentially worth more than $3 billion. In addition, the company will receive royalties from the products they develop.

GO Prime with only $1.49 now

LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top